Eastman Kodak Company (KODK)

Executive Summary / Key Takeaways

• Balance Sheet Reinvention Through Pension Engineering: Kodak's termination of its legacy pension plan delivered $1.02 billion in excess assets, enabling debt reduction from $700 million to $300 million and creating the strongest liquidity position in decades. This eliminates the "going concern" overhang that capped valuation and frees $40 million annually in interest expense, directly improving earnings power.

• Segment Divergence Defines the Investment Case: While the Print segment (67% of revenue) struggles with 0% EBITDA margins and structural decline, Advanced Materials & Chemicals (AM&C) is accelerating with 17% revenue growth and 129% EBITDA growth at 12% margins. This bifurcation suggests the market should value Kodak on its growth engine, not its legacy anchor.

• Tariff Moat Creates Defensible Niche: As the sole U.S. manufacturer of lithographic plates, Kodak secured ITC-imposed duties of 115-317% on Chinese and Japanese imports, establishing a protected domestic market. This creates pricing power and stabilizes cash flow from the declining Print segment, buying time for the AM&C pivot.

• Manufacturing Expertise as Optionality: Kodak's 79,000 patents and century of coating chemistry expertise are being redeployed into high-value markets—pharmaceutical manufacturing, battery materials, and functional films. This provides asymmetric upside if any initiative achieves commercial scale.

• Valuation Disconnect Reflects Transition Risk: Trading at 0.85x EV/Revenue and 5.0x EV/EBITDA with $337 million in cash against $300 million in debt, the stock prices in minimal value for the AM&C growth trajectory. The key risk is execution: can management grow AM&C fast enough to offset Print decline while deploying new initiatives profitably?

Setting the Scene: Kodak 2025 Is Not Your Father's Film Company

Eastman Kodak Company, founded in 1880 and incorporated in New Jersey in 1901, has spent the past decade shedding its identity as a consumer film manufacturer to become a specialized industrial materials and printing technology provider headquartered in Rochester, New York. The company generates $1.07 billion in annual revenue through three distinct segments: Print (67% of revenue, 0% EBITDA margin), Advanced Materials & Chemicals (AM&C) (30% of revenue, 12% EBITDA margin), and Brand licensing (2% of revenue, 87% EBITDA margin). This mix reveals a business in transition—one foot planted in a declining legacy market, the other stepping into higher-value industrial applications.

The company leverages 130 years of research and 79,000 patents in coating, chemistry, and materials science. The company no longer competes in consumer photography; instead, it serves commercial printers, pharmaceutical manufacturers, motion picture studios, and industrial film users. The Print segment provides lithographic plates, inkjet presses, and workflow software. AM&C supplies specialty chemicals, motion picture film, and pharmaceutical ingredients. Brand licensing monetizes the iconic Kodak name through third-party partnerships.

The industry structure presents both headwinds and tailwinds. Traditional commercial print faces digital substitution and pricing pressure, with global volumes declining 1-2% annually. However, specialty chemicals and functional materials enjoy growing demand from reshoring trends, sustainability mandates, and advanced manufacturing needs. Kodak sits at this intersection, using its legacy infrastructure—particularly the Eastman Business Park manufacturing hub—to serve niche markets where its deep technical expertise creates defensible positions.

Technology, Products, and Strategic Differentiation

The Coating Chemistry Moat

Kodak's core technological advantage lies in its proprietary coating and deposition processes, refined over decades of film manufacturing. This expertise enables products like KODAK SONORA Process Free Plates, which eliminate chemical processing, water, and energy waste for commercial printers. This transforms a cost center—environmental compliance and chemical disposal—into a value proposition, allowing Kodak to command premium pricing despite intense competition. The technology delivers tangible benefits: customers reduce processing steps, cut waste by up to 90%, and improve operational efficiency, creating switching costs once integrated.

This same coating platform powers the AM&C segment's expansion. The company rebuilt its film plant and installed a new sensitizing line to address production bottlenecks, responding to a "real resurgence" in motion picture film demand—evidenced by Oscar-nominated films like The Brutalist and Anora shot on Kodak stock. This investment captures a cultural shift toward analog aesthetics in premium content, creating a durable revenue stream from a niche market with few viable suppliers.

Pharmaceutical Manufacturing: From Concept to cGMP

Kodak completed its cGMP pharmaceutical manufacturing facility at Eastman Business Park in 2025, beginning production of phosphate buffered saline (PBS) for laboratory use in the second half of the year. This represents a strategic pivot from supplying unregulated key starting materials to manufacturing FDA-regulated products. This opens a $15 billion global reagents market and positions Kodak to produce higher-value IV saline solutions and diagnostic test reagents, with Class II certification and ISO 13485 quality management systems as next milestones. Success here would transform AM&C from a materials supplier to a finished pharmaceutical manufacturer, expanding margins and addressable market.

The facility's registration with the FDA and initial PBS production demonstrate execution capability. Management emphasizes this as a "key investment for our future," with four new products already launched. Kodak is leveraging existing chemistry expertise to enter regulated markets with higher barriers to entry and stickier customer relationships.

Battery Materials and Functional Printing: Asymmetric Optionality

Kodak's $25 million investment in Wildcat Discovery Technologies in July 2022 aimed to capture EV battery material growth. While the investment was impaired by $22 million in 2025 and ultimately converted to just $4 million cash through a merger, the initiative reflects management's willingness to deploy capital into adjacent technologies. More promising is the company's pilot coating facility for battery electrodes and production-scale equipment for transparent antennas leveraging 5G expansion.

These are low-cost, high-upside bets. The transparent antenna technology applies Kodak's copper microwire printing to automotive and construction glass surfaces, addressing a market driven by RF communications proliferation. If commercialized, this could create a new revenue stream with minimal incremental investment, exploiting the same coating infrastructure used for film. The Wildcat loss demonstrates disciplined capital allocation—management recognized the impairment and exited rather than doubling down.

Financial Performance & Segment Dynamics: Evidence of Strategic Pivot

Consolidated Results: A Tale of Two Halves

Kodak's 2025 results validate the "tale of two halves" narrative. Consolidated revenue grew 2% to $1.069 billion, but the composition shift is more telling. Gross margin expanded 3 percentage points to 22%, driven by pricing discipline and operational streamlining. Operational EBITDA surged 138% to $62 million, reflecting the payoff of $200 million in operating expense reductions over recent years.

The company is achieving operating leverage despite revenue headwinds, proving that "smart revenue"—shedding unprofitable business while raising prices in defensible niches—works. The 2% top-line growth masks a 17% expansion in AM&C offsetting a 3% Print decline.

The GAAP net loss of $128 million versus $102 million income in 2024 is largely due to one-time items: a $153 million excise tax on the KRIP reversion and $7 million debt extinguishment loss, partially offset by a $66 million pension settlement gain. Adjusting for non-recurring items, the net loss was $11 million compared to $87 million prior-year income—a $98 million deterioration driven primarily by $111 million less non-cash pension income. Core operational performance is stabilizing, and the pension headwind will dissipate in 2026 when pension income drops to just $2 million, making year-over-year comparisons cleaner.

Print Segment: Managed Decline with Pricing Power

Print revenue fell 3% to $715 million, with volume declines across all sub-segments (Prepress -$40M, Prosper -$4M, EPS -$16M, Software -$2M). Yet operational EBITDA fell to just $3 million, a 0% margin. While pricing improvements added $27 million to gross profit (+$19M Prepress, +$7M Prosper, +$3M EPS), this was countered by $11 million higher manufacturing costs, $9 million aluminum cost inflation, and $7 million lower Prepress volumes.

Kodak has pricing power in its core plate business—customers will pay more for the only U.S.-manufactured product—but commodity inflation and volume erosion are squeezing profitability. The segment is in managed decline, with the tariff protection (duties up to 317% on imports) providing a floor for domestic pricing but not enough to restore growth. Management's investment in AI-enabled service systems and the PROSPER ULTRA 520 press moving to full production may slow the decline, but the segment's primary role is cash generation to fund AM&C expansion.

AM&C Segment: The Growth Engine

AM&C delivered the thesis-affirming performance: revenue up 17% to $316 million, operational EBITDA up 129% to $39 million, margin expanding from 6% to 12%. Growth was broad-based—Industrial Film and Chemicals added $18 million from pricing and $13 million from volume; Motion Picture added $8 million from pricing and $6 million from volume. The segment now represents 30% of revenue but 63% of operational EBITDA, making it the de facto profit driver.

The segment is hitting an inflection point where scale drives margin expansion. The 12% EBITDA margin still trails the 40%+ margins of pure-play materials companies, indicating room for improvement as the pharma facility ramps and film capacity utilization increases. Management's commentary that investments are "starting to see the results truly pay off" suggests this trajectory continues.

The concentration risk is notable: Kodak Alaris represents 33% of AM&C revenue. However, this also reflects the strategic value of Kodak's materials—Alaris depends on Kodak film for its own business, creating a stable demand base. Revenue quality is high, with sticky industrial customers unlikely to switch suppliers.

Brand Segment: High-Margin Cash Generation

Brand licensing generated $23 million in revenue (+15%) and $20 million in EBITDA (+17%), an 87% margin. This is profit from trademark monetization. This segment requires zero capital investment and grows organically, funding R&D and debt reduction. International expansion, particularly in Asia where Kodak-branded apparel stores are opening, demonstrates the brand's enduring value among younger consumers. While small, this segment provides ballast to the income statement and validates Kodak's cultural relevance beyond its industrial businesses.

Balance Sheet & Capital Allocation: From Fragility to Flexibility

The pension reversion transformed Kodak's financial position. As of December 31, 2025, the company held $337 million in cash against $300 million in term loans and Series B preferred obligations, a net positive position. The $312 million debt paydown in November 2025 reduced the term loan to $200 million, saving approximately $40 million annually in interest expense.

The company moved from a "going concern" disclosure in Q2 2025 to a "strongest balance sheet in many years" by year-end. This eliminates refinancing risk and provides strategic optionality. The March 2026 amendments extended the Series B mandatory redemption to June 2029 and required an additional $100 million term loan paydown, further de-risking the capital structure. Management's plan to use $100 million to retire higher-interest debt (12.5% rate) reduces weighted-average interest costs and frees cash for growth.

The Series B terms became less favorable—dividend rate increased from 4% to 6% and conversion price lowered from $10.50 to $10—but the extension was critical. Management prioritized financial stability over dilution risk, a prudent trade-off given the company's recent fragility. With $144 million in net cash received and $158 million in investment assets (to be converted primarily in 2027-28), Kodak has a multi-year liquidity runway.

Capital allocation priorities are clear: deleverage first, then fund AM&C growth. The $45-55 million expected capex for 2026 is modest relative to cash flow, suggesting disciplined investment.

Competitive Context: Protected Niche vs. Scale Players

Kodak competes against printing giants—HP Inc. (HPQ), Canon (CAJ), Fujifilm (FUJIY), and Xerox (XRX)—each with 10-25x larger revenue bases. HPQ's $55 billion in revenue and 20-25% market share in production printing dwarf Kodak's $1 billion scale. Canon's $30 billion revenue and 15-20% market share reflect global distribution and R&D resources Kodak cannot match. Fujifilm's diversification into healthcare and materials mirrors Kodak's strategy but on a $22 billion revenue base.

Scale disadvantages are real—Kodak's 2.5% revenue growth lags competitors' 3-7% rates, and its 22% gross margin trails Canon's 40%+ and Fujifilm's 40%+. However, Kodak has carved defensible niches where scale is less important than specialized capability. The tariff victory is decisive: duties of 115-317% on imported plates effectively wall off the U.S. market from low-cost Asian competition. As the sole domestic plate manufacturer, Kodak can maintain pricing and market share despite its small size. This is not a growth driver but a strategic moat that preserves cash flow from decline.

In inkjet presses, Kodak's PROSPER 7000 Turbo claims the title of "world's fastest inkjet press machine" at 400 meters per minute, with upgradability from the PROSPER 6000 offering a 35% speed increase at minimal cost. This competes with HP's PageWide and Canon's imagePRESS systems. While HP and Canon have broader distribution, Kodak's advantage lies in inline finishing options and integration with its chemical expertise—printers buy the press and lock into Kodak's consumables, creating recurring revenue. Kodak can compete on performance in specific applications but lacks the scale to dominate the market.

The AM&C segment faces different competition. In motion picture film, Kodak is one of few remaining suppliers, benefiting from industry consolidation and the analog resurgence. In specialty chemicals, it competes with diversified chemical companies but differentiates through custom coating capabilities and small-batch production that larger players find uneconomical. The pharma facility enters a regulated market with high barriers, where Kodak's existing quality systems provide an edge over new entrants.

Outlook, Guidance, and Execution Risk

Management's guidance frames 2026 as a year of execution. The company expects $45-55 million in capex, primarily directed at AM&C capacity expansion and pharma facility qualification. Pension income will drop to $2 million, eliminating a major non-cash earnings contributor but providing cleaner comparability. Approximately 20% of unrecognized revenue from performance obligations will be recognized in 2026, providing $50-60 million of visibility.

The central assumption is that AM&C's 17% growth trajectory continues while Print's decline moderates. Management's commentary emphasizes that investments are "paying off" and that the PROSPER 520 and 7000 presses moving to full production will drive "additional growth and better margins." Kodak expects Print EBITDA to recover from 0% as new products gain traction and tariff protection stabilizes pricing.

Execution risks are material. The AM&C segment's 12% EBITDA margin, while improved, remains well below industrial materials peers, suggesting either underutilization or cost structure inefficiencies. The pharma facility's progression from PBS production to IV saline and regulated drugs requires FDA approvals and customer qualification—a multi-year process with uncertain outcomes. The battery materials initiative, evidenced by the Wildcat loss, shows Kodak can misallocate capital in emerging tech.

Management's "smart revenue" strategy—shedding unprofitable business—has slowed overall growth but improved margins. The risk is that Print declines faster than AM&C can compensate, compressing overall EBITDA. With Print still representing two-thirds of revenue, even modest acceleration in its decline could overwhelm AM&C's gains.

Risks and Asymmetries

Thesis-Threatening Risks:

• Print Segment Meltdown: If volume declines accelerate beyond the current 3% rate or aluminum/raw material costs spike again, Print EBITDA could turn negative, dragging overall results down faster than AM&C can grow. The tariff moat protects against imports but not against domestic economic slowdowns or customer shifts to digital alternatives.

• AM&C Growth Deceleration: The 17% growth rate depends on film resurgence continuing and pharma facility ramping. If motion picture demand proves cyclical or pharma qualification delays extend beyond 2026, the segment's trajectory could flatten. Kodak Alaris' 33% revenue concentration creates customer-specific risk.

• Capital Allocation Missteps: The Wildcat investment loss shows management can overpay for growth options in unfamiliar markets. If the company diverts cash flow into more speculative battery or AI initiatives rather than expanding core AM&C, returns could suffer.

Asymmetric Upside:

• Pharma Facility Breakthrough: If Kodak achieves Class II certification and secures contracts for regulated IV solutions, the pharma business could scale rapidly. The global IV saline market exceeds $3 billion; capturing even 5% would add $150 million in high-margin revenue, potentially doubling AM&C EBITDA.

• Transparent Antenna Commercialization: Success in 5G antenna applications could create a new materials business with minimal incremental capex, leveraging existing coating assets. While speculative, the market for transparent conductive films is growing 15% annually—Kodak's IP could capture meaningful share.

• Debt-Free Conversion: If Kodak uses remaining cash to fully repay the $200 million term loan by 2027, interest savings would boost EBITDA by $25 million annually, improving valuation multiples and strategic flexibility.

Valuation Context

At $11.25 per share, Kodak trades at an enterprise value of $911 million, or 0.85x trailing revenue and 5.0x operational EBITDA. These multiples sit well below printing equipment peers (HPQ: 0.46x revenue, 5.8x EBITDA; CAJ: 0.85x revenue, 5.9x EBITDA) and industrial materials companies (FUJIY: 9.0x EBITDA). The discount reflects Kodak's net loss profile and historical volatility.

The market is pricing Kodak as a declining print business rather than a transforming materials company. The EV/Revenue multiple of 0.85x assigns minimal value to AM&C's 17% growth trajectory. For context, if AM&C were valued as a standalone industrial materials business at 1.5x revenue (a conservative peer multiple), its $316 million revenue would be worth $474 million—more than half the total enterprise value, leaving Print and Brand as essentially free options.

Cash flow metrics tell a more nuanced story. The company generated $480 million in operating cash flow and $446 million in free cash flow in 2025, but $618 million came from the KRIP reversion, making the underlying run rate harder to discern. The price-to-operating cash flow ratio of 2.3x appears attractive but includes one-time pension benefits. Excluding KRIP, operating cash flow was roughly break-even, consistent with the $11 million adjusted net loss.

The balance sheet strength is real: $337 million in cash against $300 million in debt provides net liquidity of $37 million, with an additional $100 million in investment assets to be received by 2028. This net cash position is rare for a company with sub-investment grade history and provides downside protection. Investors are getting the operating business for roughly its net debt-adjusted enterprise value, with the pension assets providing a margin of safety.

Conclusion

Kodak's investment thesis hinges on a simple proposition: a transformed balance sheet and tariff-protected Print business can fund a profitable pivot toward Advanced Materials & Chemicals while providing optionality on pharmaceutical manufacturing and functional printing. The $1.02 billion pension reversion was the catalyst that converted a financially fragile legacy company into a viable industrial platform with strategic flexibility.

The critical variables are execution velocity in AM&C and stabilization of Print. If AM&C maintains 15%+ growth and expands margins from 12% toward industrial peer levels of 20%+, the segment could generate $60-80 million in EBITDA by 2027, supporting a valuation well above current levels. Simultaneously, Print must avoid becoming a cash drain; the tariff moat and PROSPER press launches should maintain at least break-even EBITDA, preserving the segment's role as a funding source.

The stock's 0.85x EV/Revenue multiple reflects skepticism that this transformation will succeed. However, the net cash position, reduced interest burden, and proven pricing power in protected markets create a favorable risk/reward asymmetry. Investors are paying for the declining Print business while getting the AM&C growth engine and pharma/battery optionality essentially for free. Whether that proves a bargain depends on management's ability to scale AM&C faster than Print declines—a race that should become clearer by mid-2026 as pharma facility revenues materialize and tariff impacts fully flow through.